# A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

> **NCT04309474** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 121 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** Elezanumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04309474
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2024-04-18
- **Final completion:** 2024-12-23
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309474, "A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04309474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*